US Appeals Court Decision On Ampyra Favors Generics Players

A US Court of Appeals has ruled in favor of three US generics players by denying Acorda’s petition to rehear litigation en banc, following the court’s finding that four patents shielding its Ampyra (dalfampridine) are invalid.